Login / Signup

Aripiprazole for the treatment of schizophrenia: Recommendations of a panel of Spanish experts on its use in clinical practice.

David FraguasDavid Almenta GallegoSergio Arques-EgeaMarcos Gómez-RevueltaCarlos Gómez Sánchez-LafuenteDaniel Hernández HuertaDaniel Núñez AriasBeatriz Oda Plasencia-GarcíaCarlos Parro-TorresSamuel Leopoldo Romero-GuillenaElena Ros CucurulCecilio Alamo
Published in: International journal of psychiatry in clinical practice (2022)
We recommend considering aripiprazole as first treatment option in the early stages of schizophrenia and in patients with affective symptoms and contemplating a switch to aripiprazole LAI in all candidate patients. Importantly, switches from other antipsychotics should consider previous antipsychotic history and exposure to aripiprazole. KEYPOINTSAripiprazole can be considered as first treatment option in early stages of schizophrenia and in patients with significant affective symptoms.Aripiprazole LAI shows better adherence than oral aripiprazole and could be considered in all candidate patients.Before switching to aripiprazole, detailed information about previous antipsychotic history should be gathered.Switch to aripiprazole should be managed differently for aripiprazole naïve and non-naïve patients.Rigorous and controlled studies on antipsychotics in real clinical practice should be carried out.
Keyphrases
  • end stage renal disease
  • bipolar disorder
  • clinical practice
  • ejection fraction
  • peritoneal dialysis
  • prognostic factors
  • physical activity
  • insulin resistance
  • patient reported